The discontinuation is voluntary and is not related to product quality, safety or efficacy.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women.
Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up.
Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug UsersMay 10, 2018
The investigators suggest that enrollment in a methadone maintenance therapy program may be helpful in providing access to HCV care in people who inject drugs.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.
Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.
Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.
Future research should develop interventions to increase HCV screening with special focus on groups demonstrating significantly lower screening rates, such as Hispanics and women.
Alcohol dependence has deleterious effects on frontal cortical volumes that are compounded by hepatitis C virus infection and drug dependence.
HCV eradication by DAA improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
No HCV infection was detected in patients receiving HCV-infected kidneys 12 weeks following treatment.
A case of remission of psoriasis after treatment of chronic hepatitis C virus has been described.
The hepatitis C treatment, sofosbuvir was found to be effective against Zika virus in a preclinical trial.
Reduced DAA delays and denials for patients with HCV reduced with provider-pharmacy collaboration.
State medical surveillance data suggest that the risk for mother-to-infant vertical transmission of hepatitis C virus is increasing.
Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin demonstrated high rates of adherence and SVR in different HCV patient subgroups, including patients with advanced fibrosis combined with chronic comorbidities.
Investigators evaluated whether unfavorable outcomes were prevented once sustained virologic response was achieved in older adults with HCV.
Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.
The advent of direct acting antiviral (DAA) agent therapies has resulted in significant improvements in treatment rates for those with co-infection.
Hepatitis B and hepatitis C may increase mortality risks in patients with HIV.
The highest SVR12 rates were obtained with 12 weeks of LDV/SOF+RBV in noncirrhotic participants and by extending the duration of LDV/SOF treatment to 24 weeks in cirrhotic individuals.
The combined presence of alcohol abuse, HBV, and HCV generates an additive effect on the risk of cirrhosis in women than in men.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
High aspartate aminotransferase levels completely mediated the effects of HBV infection on any cataract.
Drinking 3 or more cups of coffee per day halves all-cause mortality risk in patients co-infected with HIV/hepatitis C virus.
Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.
Updated labeling has been provided for several treatments for hepatitis C virus infections.
Study evaluated the optimal duration of ledipasvir/sofosbuvir for the treatment of acute hepatitis C virus (HCV) infection in HIV.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Importance of PrEP for People Involved in Criminal Justice Systems
- Increasing Incidence of Syphilis in People With HIV
- FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents
- Fungal Infections of the CNS: Diagnostic and Treatment Approaches
- Study Supports Development of a Vaccine for Recurrent Vulvovaginal Candidiasis
- Early Flow Cytometry Predictive of Clinical Deterioration in Sepsis
- Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?
- Hepatitis C Virus Infection Linked to Gut Dysbiosis
- Two Hepatitis C Virus Infection Treatments to Be Discontinued
- Antibiotic Use During Pregnancy May Increase Risk for Childhood Asthma